Navigation Links
Avaxia Biologic's Barbara Fox Named one of Mass High Tech's Women to Watch in 2012
Date:3/1/2012

LEXINGTON, Mass., March 1, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that Dr. Barbara Fox, its founder and CEO, has been was named one of Mass High Tech's Women to Watch in 2012.  Mass High Tech's 9th annual Women to Watch awards recognize women in the fields of technology and life sciences, "who are go-getters, hardworking, inspirational and motivational to their peers."

Dr. David Poorvin, member of the Board of Directors of Avaxia, commented, "We are truly proud of this recognition of Dr. Fox's achievements.  She has been instrumental in building Avaxia Biologics from a creative idea into a developmental biotech company that will be testing its first drug candidate later this year. She is not only an innovative scientist, but also a motivational executive who leads by example.  We are confident that she will continue to have a significant impact on drug development and the biotech communities in Massachusetts for years to come."

Prior to founding Avaxia Biologics, Dr. Fox was the founder, President and Chief Scientific Officer of Recovery Pharmaceuticals, a company developing and marketing medications for the treatment of addiction. Prior to founding Recovery Pharmaceuticals in 1998, she was Vice President, Immunology at ImmuLogic Pharmaceutical Corp. She joined ImmuLogic in 1993, having served on the faculty of the University Maryland School of Medicine, Baltimore, as Associate Professor of Medicine with tenure in the Division of Rheumatology and Clinical Immunology, Dept. of Medicine. Dr. Fox received her BA in Chemistry from Bryn Mawr College and her Ph.D. in Chemistry from MIT. Dr. Fox trained as a post-doc in cellular immunology at the NIH.

Mass High Tech will honor Dr. Fox and 19 other awardees at an awards breakfast on Friday, May 11, 2012 at the Fairmont Copley Plaza.

About Avaxia Biologics, Inc.: Avaxia Biologics is a development-stage company developing oral antibody therapeutics that act locally within the gastrointestinal tract. The antibodies are designed to treat both diseases of the GI tract and metabolic diseases. Using its proprietary antibody platform, Avaxia is developing products for inflammatory bowel disease, GI acute radiation syndrome, celiac disease, oral mucositis, diabetes and obesity.


'/>"/>
SOURCE Avaxia Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Avaxia Biologics, Inc. Awarded BARDA Contract for Therapeutic Countermeasure to Help the Nation Respond to a Radiological Emergency
2. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Oral Antibody Therapeutic for Celiac Disease
3. Avaxia Biologics, Inc. to Present Key Pre-Clinical Inflammatory Bowel Disease Remission Data at Biotech Showcase 2011
4. Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Companys Synthetic Biologics Strategic Focus
5. Sumagen Initiates Clinical Testing of Omnia Biologics Manufactured HIV Vaccine
6. Adeona Announces Proposed Name Change to Synthetic Biologics, Inc., and Appointment of John Monahan, Ph.D., as Senior Vice President of Research & Development
7. BioMarin Receives Positive Opinion from European Regulatory Authorities for Expanded Biologics Manufacturing Facility
8. Treatment of Patients With Malignant Mesothelioma Utilizing Photodynamic Therapy With Pinnacle Biologics Compound PHOTOFRIN® - Obtains FDA Orphan Drug Designation
9. ResearchMoz: Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)
10. US Biologics Market
11. BioMarin Announces FDA Approval of Expanded Biologics Manufacturing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... company focused on the development of oral drug delivery ... meeting with the U.S. Food and Drug Administration (FDA) ... At the meeting, the ... submission of ORMD-0801, would be a Biologics License Application ...
(Date:9/1/2017)... 1, 2017  Bayer will present the latest research from ... Medical Oncology (ESMO) 2017 Congress, September 8-12 in ... preclinical and clinical data on Bayer,s marketed portfolio and late-stage ... "We value the ... cancer research at ESMO," said Carsten Brunn , Head ...
(Date:8/29/2017)... , Aug. 29, 2017 In a ... security, and regulatory compliance for veterinary practices of all ... a new partnership that makes TITAN,s expertise in physical ... available to Cubex,s clients nationally. ... buying and handling controlled substances is at risk today," ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... 19, 2017 , ... The ISO 9001 standard sets out the requirements for ... efficient and improve customer satisfaction. ISO 9001:2015 was released in 2015 and certified organizations ... of September 2018. , As described in this white paper , ...
(Date:9/19/2017)... ... September 19, 2017 , ... Bone Solutions Inc. ... its magnesium-based orthopedic medical device, OsteoCrete®. OsteoCrete® bone void filler is designed to ... to incorporate magnesium, a critical property for bone health and development. , “We’re ...
(Date:9/19/2017)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... of its Pflugerville- FM 685 facility. , “We are pleased to announce Dr. ... said Dr. Stephen Van Roekel, Reginal Medical Officer of First Choice Emergency Room – ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... country with the Davidson Fellows Scholarship on September 27 at a reception in ... Science, Technology, Engineering, Mathematics, Literature and Music. , “I am honored to be ...
(Date:9/19/2017)... Houston, TX (PRWEB) , ... September 19, 2017 ... ... redesign and update their mobile app offering. The new app provides a modern ... adherence and the overall shopping experience. , The fred’s Pharmacy mobile app includes ...
Breaking Medicine News(10 mins):